a momentum our very morning following first our this with is especially strong interest your and what in leading for business. had core Gvoke Good and with morning. priority. #X in all second listening. a our who's with to maintaining the discussion shown -- Allison. Xeris We've and Xeris progress quarter, Thanks, everyone indicators steady clearly consistent strong We appreciate quarter
announced move our transitioning also business process a company a number disease key pharma the focused achievements. in well rare specialty We major as and of of commercially to as other a
I'll was major and acquisition becoming highlight a increases Equally pharma remarks. with of announcement detail of second proposed as highlights. focused, start important the the the of driven demand strong Gvoke, specialty rare I'll that several sales, commercially impressive to more my with discuss we'll metrics evidenced disease in more which Biopharma, HypoPen few The the you shortly. major was key quarter for the well in by share as a company, continued Strongbridge follow-on by in a step
an mini-dose moving temperature. from We approval exercise-induced Oxford-SVB hypoglycemia feedback population, and great to Gvoke a EU study an well. and on we that quarter prefilled best in at program based interim feedback, which cash also broader determined extend to venture to milligram II program XX further FDA of terminate found as to in the FDA our micro-dose, it the runway. territory. our We debt diabetes Phase shelf advance facility U.K. life syringe, during extended received -- talk X our partner in for and of commercialization prioritize We renegotiated Tetris the was months hypoglycemia Ogluo we'll Pharma HypoPen And a room XX months prevention about post-bariatric with the prevention
has and foundation beginning Gvoke a to Since strong Gvoke. our growth with HypoPen, accelerate. start me of Let launch is been built the
market the to XX% yet growth second is have market of showed in modest X% back XX% growth to pre-pandemic of overall growth that not quarter. seen, Although the we
However, our overall XX% outpacing prescription and approaching the from XX% is market market first new quarter by glucagon share market. second now significantly improved of of the June, the quarter at the in the end
quarter. modest Gvoke and do the sales innovative Compared prescribers were XX% also We've of direct to were see in of by up in quarter. XX% like second signs sales Gvoke Gvoke number the was XX% acceleration, brands of volume same the quarter, net by first prescription customers the ready-to-use unique quarter. Gvoke. in second and the increased in driven We wholesalers XX% to up up unit the the quarter,
manufacture. in returns X-milligram extremely only we prior gross product the reflected important; event, think mentioned, being dating now sold The end one, two, PFS and sales as wholesaler that from to has indirect which, I for result impacted the our HypoPen, see is $X number, was and negatively XXXX. We gross a performance June not a to don't sales XX-month the which our of by: especially net the was continuation level mostly as returns at recurring fully co-pay, net of strong very to
We've approaching quarter diabetes the drive currently the physicians With endocrinologists back-to-school currently our pediatric to to to fast decile expanded are with are prescriptions. inside people periodic an ready-to-use approximately physicians. We're care in our primary insulin-taking critical target million-plus and spike don't group, campaign These and able momentum including season. top launching people, we expand sales XX,XXX glucagon. glucagon who in customer-facing developed approximately X seeing our integrated with natural during force prescribing sales endocrinologists the effort now glucagon XXX endocrinologists, carry to third pediatric
Of this back-to-school we assuming course, have a normal more is this year.
what country, of variant school and we'll nature the around returning country, due again the see reopenings see in-person children be to anxiously awaiting to looks school. we're We'll we Delta As COVID the the around monitoring closely like. resurging
of I pricing the reimbursed originally and Turning ex-U.S. to kits. European Ogluo We Ogluo very in with EU. and in the Novo as everyone this legacy having approach based process U.K. of remind brand. glucagon our the want potential viewed territory to limited our on
few to would analyzed and to only. in region assumption contracted in launch the countries the thus losing strategy looking select prices select In Therefore, then a market the only we'll for and anywhere -- distributors kits. not launch rather we of self-pay the but reimbursed prices then, had reimbursed fact, our reported be after in proposition be that going-in viable partner, We were markets. was commercial a for legacy
higher-than-expected the countries countries What levels many the success getting changed XXXX reimbursed. yet reimbursed well and in are prices which even early pricing as of successful people the out pocket was they're Lilly is where paying of -- the in Lilly not launch in as the at
XXXX of April of result, in at we U.K. end our and and As approval EU since had partnering the started the the Ogluo's outbound February a outreach. in inbound XXXX, own inquiries and several in of also
Speaking potential partners. with several
be would whom name We're found, company. to weeks Ogluo and in ago, U.K.-based by the And a overall few a put as it had who announced necessary for and and companies. up and and a to team of very know, we organization. they're They're company their a in scaling that the we launch, EU. excited across highly U.K. complementary success is partner. entrepreneurial you pharmaceutical leadership for their experienced expanding founded Tetris also individuals company pronounce to the Essentially, whom to prioritize hands into Our success attention priority would getting was territory. Ogluo, would -- critical attention needed the it is absolutely making Ogluo deserves, a be success in of it a get hard of time the -- of from to Tetris, for that be as a for their the Ogluo kind a great success U.K. partner international approach by in a
Tetris as potentially receive the as Starting in mid-single-digit is XXXX could the this milestones U.K. countries and sale country and first launched be up on sales. net time secured. tied Tetris individual later subsequently and that in years, anticipates in launch Ogluo to will over payments and available sales-related pricing royalty reimbursement million $XX several subsequent other as collecting commercial year well additional to and a in
programs. Now provide micro-dose, update let and our on me glucagon ready-to-use an mini-
to our As and order programs. ready-to-use FDA months a the several glucagon reasonable mini- spent with clinical micro-dose in past we've the dialogue in we've advance to reported, pathway trying find
FDA As you programs. have made all In both post-bariatric we Phase need feedback We've prevention prevention programs too hypoglycemia, complex new III III work this the at full on both development hypoglycemia the into of and recall, decisions on are us enter and for and the costly far exercise-induced Phase to point any program. Phase short, either that is requirements contemplate III. of gotten these for to
development. have PBH, For discontinued we further clinical
twice patients. develop patients examine broader a the and EIH, data we range and type efficacy execute hypoglycemia in exercise-induced and specific For least That long-term of use requirements, prevention to and at study Phase will of safety that exercise an X additional in of II a -- X week. FDA on based type feedback underlying
We will in early anticipate the initiating XXXX. study
the focus to are on going With Now own we'll the Biopharma especially potential the of pipeline. to close efforts forward, rest the business, intensified commercial commercialization. approach for development of acquisition, focus on reprioritizing Strongbridge with solely and our our our pipeline, on products our we the our anticipated
XeriSol develop that? pramlintide-insulin Xeris proven combination, these companies. II. intended do to to, liquid and broadly what for towards The by we're I products was mean diazepam them technology development was the glucagon; clearly, products, further is that prove our with technology beyond other first, out-license these second, applicable to to Now our like First, never intent development We've stable applicable. Phase and beyond
difficult. more development said, landscape program of However, will XeriSol changed for That co-formulation look pramlintide-insulin commercialization continue rapidly our out-licensing our we to diazepam making program. and the has partners to advance both competitive rather and
is to goal find Our suitable partners.
resources will otherwise spend on assets. we additional not advancing However, these
endocrinology primary have area we focus potential adjacent underway. X an undisclosed will of and our a and current commercial programs for development and continue in our they in commercialization advance which We in gastroenterology have to therapy as program area development high
also to create to in competitive whom such may advantage. companies, the our science X speak. to as partners programs continue top for and currently that in on a unique potential in continue proof-of-concept, will we all look our and technologies additional and/or companies pharma we're have advance out-license formulation projects We discussions XX We for
acquisition to mind why the for Xeris. this in Now I'd combination our the Strongbridge like is spend time discussing Biopharma revisiting some perfect and
by scalable products. and bringing rare diversified biopharmaceutical and First, a specialty oriented we're and Xeris disease creating together, increasingly Strongbridge towards more company
will growing revenue rapidly Gvoke with X have KEVEYIS. a base stronger assets, We and
approval, leverage we subject FDA positioned to be launch We will a market. experienced, will RECORLEV well RECORLEV. have to infrastructure to bring also opportunity Xeris' endocrinology-focused And the commercial near-term for to of
in of than RECORLEV, potential enabling greater envisioned launch had Our for Strongbridge endocrinology launch. a reach at commercial the larger footprint is
have We in of an we patients. a range rare and add additional also broader will overall which endocrinology-focused into can disease commercial infrastructure robust products more benefit
disease stronger rare brought new our to for platforms scalable We technology products expect development formulation potential unique and a XeriSol foundation, of rare our specialist-oriented these opportunity forward that we on participate and in endocrinology, infrastructure late-stage and put using to will and focused XeriJect. gastroenterology be the from see and areas and Furthermore, diseases. commercial products with the and in financial also into neurology, companies therapeutic larger continued products of strategic consolidation
we We importantly, and significant will also stakeholders have substantial cost of significant believe value will realize to shareholders. And to to this avoidance. all enhanced our combination potential drive and position synergies the us for benefits provide
and I leader guide were need of company. to Now of would readying a pending finance change our just next stage and briefly commercially I our into we the as April more have close reporting quarter, for our XXXX, of for we for -- a team years, important built and and transitioning debt the to leader stage. for that of team larger out IPO. a has development-stage that a X Barry that our team efforts could increasingly role Barry the our as in believe Xeris about needs financing an in It the finance finances culminating was as and stewarded public Strongbridge superb last appropriate CFO. our company the build our Deutsch specifics the complicated that In talk company stepped the new finance who we focused, want acquisition.
what he's finance. We been been Pieper for Steve a our background as Steve has is in it I'll And everything tapped significant the financial has to Xeris stage to development. Barry company. highlights as performance. Barry I And the turn of review Steve for to and next believe of has to needs commercial years, want our for I the CFO. role. the for want succeed Barry such, to several Steve over now Steve And thank mentoring to recently our welcome done
